Dr. Hui Cheng is a professor and principal investigator at the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College in China. He received his BS degree from Zhejiang University in 2007 and his PhD from Peking Union Medical College in 2013, establishing his independent laboratory in 2019. His research delves into hematopoietic stem cells (HSC) and the bone marrow niche, focusing on: 1) uncovering the earliest colonization of human HSC in fetal bone marrow, providing insights into their molecular features and the bone marrow microenvironment's role in HSC maintenance; 2) elucidating the molecular mechanisms that balance self-renewal and differentiation in adult HSC; and 3) revealing how niche cells and their secreted mediators regulate normal HSC and influence disease development. As a senior author, Prof. Cheng has published his work in prestigious journals, including Cell Stem Cell, Immunity, Circulation, Blood, Journal of Experimental Medicine, Journal of Clinical Investigation, Nature Communications, Haematologica, and Cell Reports.
PhD, Internal Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 2007-2022
BS, Bioinformatics, College of Life Sciences, Zhejiang University, Hangzhou, China, 2003-2007
Professor of Medicine and Stem Cell Biology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 2020-
Associate professor of Medicine and Stem Cell Biology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 2015-2020
Visiting scientist, Weizmann Institute of Science, Israel, 2016-2017
Research Associate, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 2015-2015
PRINCIPAL HONORS, AWARDS:
2024 Fok Ying Tung Education Foundation (FYTEF) Awards
SELECTED PUBLICATIONS:
1. Lv H, Wang C, Liu Z, Quan M, Li K, Gou F, Shi X, Liu Q, Yu Y, Zhu P, Cheng H*, Cheng T*, Ai D*. Suppression of the Prostaglandin I2-Type 1 Interferon Axis Induces Extramedullary Hematopoiesis to Promote Cardiac Repair After Myocardial Infarction. Circulation. 2025
2. Pu S, Cheng T*, Cheng H*. Advances in RNA editing in hematopoiesis and associated malignancies. Blood. 2025
3. Wang N, Yang S, Li Y, Gou F, Lv Y, Zhao X, Wang Y, Xu C, Zhou B, Dong F*, Ju Z*, Cheng T*, Cheng H*. p21/Zbtb18 repress the expression of cKit to regulate the self-renewal of hematopoietic stem cells. Protein & Cell. 2024
4. Zheng Z, Yang S, Gou F, Tang C, Zhang Z, Gu Q, Sun G, Jiang P, Wang N, Zhao X, Kang J, He Y, Yang M, Lu T, Lu S, Qian P*, Zhu P*, Cheng H*, Cheng T*. The ATF4-RPS19BP1 axis modulates ribosome biogenesis to promote erythropoiesis. Blood. 2024
5. Li M, Sun G, Zhao J, Pu S, Lv Y, Wang Y, Li Y, Zhao X, Wang Y*, Yang S*, Cheng T*, Cheng H*. Small extracellular vesicles derived from acute myeloid leukemia cells promote leukemogenesis by transferring miR-221-3p. Haematologica. 2024
6. Li J, Liu J, Li Y, Chen L, Cheng H*, Li Y*, Cheng T*, Wang Q*, Zhou B*. Differentiation route determines the functional outputs of adult megakaryopoiesis. Immunity, 2024, 57(3): 1-17
7. Lin Y, Gu Q, Lu S, Pan Z, Yang Z, Li Y, Yang S, Lv Y, Zheng Z, Sun G, Gou F, Xu C, Zhao X, Wang F, Wang C, Yuan S, Xie X, Cao Y, Liu Y, Gu W*, Cheng T*, Cheng H*, and Hu X*. Ruxolitinib improves hematopoietic regeneration by restoring mesenchymal stromal cell function in acute graft-versus-host disease. Journal of Clinical Investigation. 2023;133(15):e162201
8. Zheng Z, He H, Tang X, Zhang H, Gou F, Yang H, Cao J, Shi S, Yang Z, Sun G, Xie X, Zeng Y, Wen A, Lan Y, Zhou J, Liu B*, Zhou B*, Cheng T*, Cheng H*. Uncovering the emergence of HSCs in the human fetal bone marrow by single cell RNA-seq analysis. Cell Stem Cell. 2022;29(11):1562-1579 e1567.
9. Sun G, Gu Q, Zheng J*, Cheng H*, Cheng T*. Emerging roles of extracellular vesicles in normal and malignant hematopoiesis. Journal of Clinical Investigation. 2022;132(18).
10. Yang S, Sun G, Wu P, Chen C, Kuang Y, Liu L, Zheng Z, He Y, Gu Q, Lu T, Zhu C, Wang F, Gou F, Yang Z, Zhao X, Yuan S, Yang L, Lu S, Li Y, Lv X, Dong F, Ma Y, Yu J, Ng L, Shi L, Liu J*, Shi L*, Cheng T*, Cheng H*. WDR82-binding long non-coding RNA lncEry controls mouse erythroid differentiation and maturation. Journal of Experimental Medicine. 2022;219(4).
11. Wang T, Xia C, Weng Q, Wang K, Dong Y, Hao S, Dong F, Liu X, Liu L, Geng Y, Guan Y, Du J, Cheng T, Cheng H*, Wang J*. Loss of Nupr1 promotes engraftment by tuning the quiescence threshold of hematopoietic stem cell repository via regulating p53-checkpoint pathway. Haematologica. 2022;107(1):154-166.
12. Wang F, He J, Liu S, Gao A, Yang L, Sun G, Ding W, Li C, Wang F, Wang X, Zhu P, Hao S, Ma Y*, Cheng H*, Yu J*, Cheng T*. A comprehensive RNA editome reveals that edited Azin1 partners with DDX1 to enable hematopoietic stem cell differentiation. Blood. 2021;138(20):1939-1952.
13. Huang D, Sun G, Hao X, He X, Zheng Z, Chen C, Yu Z, Xie L, Ma S, Liu L, Zhou B, Cheng H*, Zheng J*, and Cheng T*. ANGPTL2-containing small extracellular vesicles from vascular endothelial cells accelerate leukemia progression. Journal of Clinical Investigation. 2021;131(1).
14. Zhang C, Xu Z, Yang S, Sun G, Jia L, Zheng Z, Gu Q, Tao W*, Cheng T*, Li C* and Cheng H*. tagHi-C reveals 3D chromatin architecture dynamics during hematopoiesis. Cell Reports. 2020;32(13)
15. Wang Y, Lu T, Sun G, Zheng Y, Yang S, Zhang H, Hao S, Liu Y, Ma S, Zhang H, Ru Y, Gao S, Yen K*, Cheng H*, Cheng T*. Targeting of apoptosis gene loci by reprogramming factors leads to selective eradication of leukemia cells. Nature communications. 2019;10(1):5594.
16. Gao A, Gong Y, Zhu C, Yang W, Li Q, Zhao M, Ma S, Li J, Hao S*, Cheng H*, Cheng T*. Bone marrow endothelial cell-derived interleukin-4 contributes to thrombocytopenia in acute myeloid leukemia. Haematologica. 2019;104(10):1950-61.